Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Austin, TX, USA, April 21, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Surgical Drill Bits Market Size, Trends and Insights By Type (Standard Solid...
-
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipelineUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in...
-
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
Alira Health, in partnership with the Autoimmune Neurology Alliance (AiNA), today announced the launch of the AXIS Registry.
-
MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat...
-
PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.
-
Centre for Neuro Skills earns second consecutive spot on Newsweek’s America’s Greatest Midsize Workplaces in Health Care 2026 list.
-
MGH collaboration to evaluate TRE-515 in ALS patients, advancing development of a first-in-class therapy targeting inflammation and nucleotide metabolism.